{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:31:58Z","timestamp":1786516318344,"version":"build-2736575974"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to evaluate the clinical efficacy, safety, and transcriptomic mechanisms of Fuzheng Yangxin Formula (FZYX) for enhanced recovery after coronary artery bypass grafting (CABG) in patients with Qi-Yin deficiency syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This prospective cohort study utilized 1:1 propensity score matching (PSM). Matched patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f144; 72\/group) received a 7-day FZYX intervention plus conventional therapy or conventional therapy alone. Assessments included the Seattle Angina Questionnaire Physical Limitation (SAQ-PL) score at 7\u202fdays, peak serum creatinine (Cr), B-type natriuretic peptide (BNP), and perioperative complications. Transcriptomic mechanisms were explored via peripheral blood RNA sequencing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Post-intervention, the FZYX group demonstrated significantly lower peak Cr (68.50 vs. 74.50\u202f\u03bcmol\/L, unadjusted\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.010; adjusted\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.0059 via ANCOVA) and peak BNP (751.00 vs. 1231.50\u202fpg\/mL,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.019). Although the difference in absolute SAQ-PL scores did not reach statistical significance for superiority (40.00 vs. 35.56,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.055), the FZYX group exhibited a markedly reduced quartile coefficient of dispersion (11.1% vs. 20.0%), indicating a trend towards a more stable physical recovery.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>FZYX appears to be a safe and promising adjunctive therapy post-CABG. While the primary endpoint was formally negative, exploratory analyses suggest it may provide target organ protection and stable physical recovery, potentially associated with modulating macrophage\/monocyte-driven innate inflammation, promoting adaptive immune reconstitution, and accelerating tissue repair.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      Identifier NCT06961136,\n                      <jats:ext-link>https:\/\/clinicaltrials.gov\/study\/NCT06961136<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1902379","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:00:25Z","timestamp":1786514425000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy, safety, and transcriptomic mechanisms of Fuzheng Yangxin formula for enhanced recovery after coronary artery bypass grafting: a propensity score-matched prospective cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Jinyang","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Cardiac Surgery, Peking University Third Hospital","place":["Beijing, China"]},{"name":"State Key Laboratory of Natural and Biomimetic Drugs, Peking University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Xiyuan Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]},{"name":"Graduate School, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyu","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochang","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Xiyuan Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]},{"name":"National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]},{"name":"State Key Laboratory of Traditional Chinese Medicine Syndrome, Xiyuan Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Ling","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Peking University Third Hospital","place":["Beijing, China"]},{"name":"State Key Laboratory of Natural and Biomimetic Drugs, Peking University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Peking University Third Hospital","place":["Beijing, China"]},{"name":"State Key Laboratory of Natural and Biomimetic Drugs, Peking University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"E18","DOI":"10.1161\/Cir.0000000000001038","article-title":"2021 Acc\/Aha\/Scai guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Lawton","year":"2022","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"ARTN 328","DOI":"10.3390\/jcm15010328","article-title":"Postoperative outcomes of minimally invasive versus conventional off-pump coronary artery bypass within an Eracs protocol: a matched analysis","volume":"15","author":"Saad","year":"2026","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.amjcard.2010.03.032","article-title":"Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy","volume":"106","author":"Turer","year":"2010","journal-title":"Am J Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ejcts.2003.12.003","article-title":"Myocardial ischemia, stunning, inflammation, and apoptosis during cardiac surgery: a review of evidence","volume":"25","author":"Anselmi","year":"2004","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.ejcts.2008.07.060","article-title":"Myocardial oxidative stress, and cell injury comparing three different techniques for coronary artery bypass grafting","volume":"34","author":"van Boven","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.jtcvs.2011.09.011","article-title":"Clinical implications and molecular mechanisms of Immunoparalysis after cardiopulmonary bypass","volume":"143","author":"Cornell","year":"2012","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1111\/jcmm.15154","article-title":"Coronary artery bypass grafting is associated with Immunoparalysis of monocytes and dendritic cells","volume":"24","author":"Perros","year":"2020","journal-title":"J Cell Mol Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"ARTN 1419169","DOI":"10.3389\/fcvm.2024.1419169","article-title":"Traditional Chinese medicine for cardiovascular disease: efficacy and safety","volume":"11","author":"Lin","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-024-03169-2","article-title":"The traditional Chinese medicine Qiliqiangxin in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial","volume":"30","author":"Cheang","year":"2024","journal-title":"Nat Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1001\/jama.2023.19524","article-title":"Traditional Chinese medicine compound (Tongxinluo) and clinical outcomes of patients with acute myocardial infarction the Cts-Ami randomized clinical trial","volume":"330","author":"Yang","year":"2023","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1161\/Cir.0000000000000182","article-title":"Secondary prevention after coronary artery bypass graft surgery a scientific statement from the American Heart Association","volume":"131","author":"Kulik","year":"2015","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"ARTN 7910","DOI":"10.3390\/jcm14227910","article-title":"Beyond lipids and platelets: a review of anti-inflammatory strategies in secondary prevention of acute coronary syndromes","volume":"14","author":"Pathangey","year":"2025","journal-title":"J Clin Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"ARTN 844","DOI":"10.3389\/fphar.2019.00844","article-title":"Traditional Chinese medicine for coronary heart disease: clinical evidence and possible mechanisms","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1004929","DOI":"10.3389\/fphar.2022.1004929","article-title":"Investigating the cardioprotective effects of Fuzheng Yangxin recipe based on network pharmacology and experimental evaluation","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1514181","DOI":"10.3389\/fcvm.2025.1514181","article-title":"A multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of Fuzheng Yangxin granule in treating heart failure with preserved ejection fraction (qi-yin deficiency and blood stasis syndrome): study protocol","volume":"12","author":"Chen","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"174742","DOI":"10.1016\/j.ejphar.2022.174742","article-title":"Ginsenoside Rg1 ameliorated experimental colitis by regulating the balance of M1\/M2 macrophage polarization and the homeostasis of intestinal flora","volume":"917","author":"Long","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/jcmm.13368","article-title":"Salidroside attenuates Neuroinflammation and improves functional recovery after spinal cord injury through microglia polarization regulation","volume":"22","author":"Wang","year":"2018","journal-title":"J Cell Mol Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2217\/rme-2021-0076","article-title":"Astragalus and human mesenchymal stem cells promote wound healing by mediating immunomodulatory effects through paracrine signaling","volume":"17","author":"Wang","year":"2022","journal-title":"Regen Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/sctm.18-0143","article-title":"Salidroside-pretreated mesenchymal stem cells enhance diabetic wound healing by promoting paracrine function and survival of mesenchymal stem cells under hyperglycemia","volume":"8","author":"Ariyanti","year":"2019","journal-title":"Stem Cells Transl Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.3892\/etm.2016.3890","article-title":"Endothelium-dependent vasodilation effects of Panax Notoginseng and its Main components are mediated by nitric oxide and cyclooxygenase pathways","volume":"12","author":"Wang","year":"2016","journal-title":"Exp Ther Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/aps.2015.146","article-title":"Ophiopogonin D maintains Ca2+ homeostasis in rat Cardiomyocytes in vitro by upregulating Cyp2j3\/Eets and suppressing Er stress","volume":"37","author":"You","year":"2016","journal-title":"Acta Pharmacol Sin"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1526653","DOI":"10.3389\/fphar.2025.1526653","article-title":"Aconiti lateralis radix praeparata ameliorates heart failure via Pi3k\/Akt\/Bnip3 pathway","volume":"16","author":"Liu","year":"2025","journal-title":"Front Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.4049\/jimmunol.2300333","article-title":"Diverse functions of C4b-binding protein in health and disease","volume":"211","author":"Werner","year":"2023","journal-title":"J Immunol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"916430","DOI":"10.3389\/fimmu.2022.916430","article-title":"Evaluation and comparison of adaptive immunity through analyzing the diversities and clonalities of T-cell receptor repertoires in the peripheral blood","volume":"13","author":"Zhuo","year":"2022","journal-title":"Front Immunol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1172\/Jci76246","article-title":"Proteinase 3-dependent Caspase-3 cleavage modulates neutrophil death and inflammation","volume":"124","author":"Loison","year":"2014","journal-title":"J Clin Invest"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"JCS263674","DOI":"10.1242\/jcs.263674.","article-title":"Dachsous is a key player in epithelial wound closure through modulating cell shape changes and tissue mechanics","volume":"138","author":"Porf\u00edrio-Rodrigues","year":"2025","journal-title":"J Cell Sci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1005821","article-title":"Dnah6 and its interactions with Pcd genes in heterotaxy and primary ciliary dyskinesia","volume":"12","author":"Li","year":"2016","journal-title":"PLoS Genet"},{"key":"ref28","first-page":"905","article-title":"Rin1 is a negative regulator of the Il3 receptor signal transduction pathways","volume":"26","author":"Hunker","year":"2006","journal-title":"Anticancer Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.4103\/1673-5374.330588","article-title":"Homer signaling pathways as effective therapeutic targets for ischemic and traumatic brain injuries and retinal lesions","volume":"17","author":"Wu","year":"2022","journal-title":"Neural Regen Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13020-024-01018-5","article-title":"Identification of molecular targets of in blood for major depressive disorder: a machine-learning pharmacological study","volume":"19","author":"Xu","year":"2024","journal-title":"Chin Med-Uk"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"106443","DOI":"10.3748\/wjg.v31.i20.106443","article-title":"Harnessing traditional medicine and biomarker-driven approaches to counteract trichostatin A-induced esophageal cancer progression","volume":"31","author":"Liu","year":"2025","journal-title":"World J Gastroenterol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.cancergen.2025.09.006","article-title":"Galectin-9 promotes Colon Cancer development by polarizing macrophages toward the M2 phenotype","author":"Zhang","year":"2025","journal-title":"Cancer Genet-Ny"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cancergen.2025.03.004","article-title":"Identification of new immune target and signaling for Cancer immunotherapy","author":"Narote","year":"2025","journal-title":"Cancer Genet-Ny"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1902379\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:00:26Z","timestamp":1786514426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1902379\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":33,"alternative-id":["10.3389\/fmed.2026.1902379"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1902379","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1902379"}}